PET-CT radiomics for immunotherapy response

IF 6.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Seminars in nuclear medicine Pub Date : 2026-01-01 Epub Date: 2025-12-13 DOI:10.1053/j.semnuclmed.2025.11.024

Alessia Artesani , Michela Olivieri , Priscilla Guglielmo , Manuela Marenco , Laura Evangelista

{"title":"PET-CT radiomics for immunotherapy response","authors":"Alessia Artesani , Michela Olivieri , Priscilla Guglielmo , Manuela Marenco , Laura Evangelista","doi":"10.1053/j.semnuclmed.2025.11.024","DOIUrl":null,"url":null,"abstract":"<div><div><em>Introduction:</em> The aim of this review is to provide a comprehensive synthesis of the current literature on the use of PET radiomics for predicting response to immunotherapy in cancer patients, as well as to discuss the main challenges emerging from data analysis and propose potential directions for its broader integration into clinical practice.</div><div><em>Materials and methods:</em> papers regarding the use of radiomics and immunotherapy by using PET/CT were selected. Some criteria were used for the selection, such as five years from the date of publication and 2) inclusion of several patients (more than 100).</div><div><em>Results:</em> Totally 24 papers were selected by using the following criteria. Most studies (<em>N</em> = 18/24; 75%) were related to the utility of radiomics for predicting immunotherapy in patients affected by lung cancer. In this setting, radiomics was able to predict the expression of PDL-1, with an important effect on the invasive procedures. In four studies, radiomics was used for predicting the prediction of response to CAR-T in patients affected by lymphoma. Emerging results are now available in patients with colon-rectal tumors and endometrial cancers, although with still limited evidence.</div><div><em>Conclusions:</em> radiomics holds substantial potential for characterizing the tumor immune microenvironment and predicting response to immunotherapy, especially in lung cancer and lymphoma.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"56 1","pages":"Pages 97-104"},"PeriodicalIF":6.6000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S000129982500176X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The aim of this review is to provide a comprehensive synthesis of the current literature on the use of PET radiomics for predicting response to immunotherapy in cancer patients, as well as to discuss the main challenges emerging from data analysis and propose potential directions for its broader integration into clinical practice.

Materials and methods: papers regarding the use of radiomics and immunotherapy by using PET/CT were selected. Some criteria were used for the selection, such as five years from the date of publication and 2) inclusion of several patients (more than 100).

Results: Totally 24 papers were selected by using the following criteria. Most studies (N = 18/24; 75%) were related to the utility of radiomics for predicting immunotherapy in patients affected by lung cancer. In this setting, radiomics was able to predict the expression of PDL-1, with an important effect on the invasive procedures. In four studies, radiomics was used for predicting the prediction of response to CAR-T in patients affected by lymphoma. Emerging results are now available in patients with colon-rectal tumors and endometrial cancers, although with still limited evidence.

Conclusions: radiomics holds substantial potential for characterizing the tumor immune microenvironment and predicting response to immunotherapy, especially in lung cancer and lymphoma.

查看原文本刊更多论文

PET-CT放射组学研究免疫治疗反应。

简介：本综述的目的是提供一个关于PET放射组学用于预测癌症患者对免疫治疗反应的当前文献的全面综合，以及讨论数据分析中出现的主要挑战，并提出将其更广泛地整合到临床实践中的潜在方向。材料与方法：选择PET/CT放射组学与免疫治疗相关的文献。我们采用了一些标准来进行选择，如从发表之日起5年，2)纳入几例患者（超过100例）。结果：按以下标准共筛选出24篇论文。大多数研究（N = 18/24;75%）与放射组学在预测肺癌患者免疫治疗中的应用有关。在这种情况下，放射组学能够预测PDL-1的表达，对侵入性手术有重要影响。在四项研究中，放射组学被用于预测淋巴瘤患者对CAR-T的反应。尽管证据仍然有限，但在结肠直肠肿瘤和子宫内膜癌患者中已经有了新的结果。结论：放射组学在表征肿瘤免疫微环境和预测免疫治疗反应方面具有巨大的潜力，特别是在肺癌和淋巴瘤中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.